This inventor holds 3 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignees: Guangzhou Baiyunshan Pharmaceutical Co., Ltd., Lumosa Therapeutics Co., Ltd., Shanghai Lumosa Therapeutics Co., Ltd.. Active years: 2006-2026.
Company Filing History:
1 out of 2 
1 out of 1 
1 out of 6 Years Active: 2006-2026
Title: Innovations of Shiqi Peng in Thrombolytic Agents
Introduction
Shiqi Peng is an accomplished inventor based in Beijing, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of thrombolytic agents. With a total of two patents to his name, his work focuses on innovative compounds that target thrombus and free radicals.
Latest Patents
Shiqi Peng's latest patents include a novel compound with effects of thrombolysis, free radical scavenging, and thrombus-targeting. This invention discloses a ternary conjugate formed by linking a thrombolytic peptide, a free radical scavenger, and a thrombus-targeting peptide. The compound is designed to form a nanospherical structure and is accompanied by a pharmaceutical composition for effective use. Another significant patent involves carboline-3-carboxylic acid modified related sequences of Ala-Arg-Pro-Ala-Lys, detailing the synthesis and application of these compounds as thrombolytic agents.
Career Highlights
Throughout his career, Shiqi Peng has worked with notable companies such as Shanghai Lumosa Therapeutics Co., Ltd. and Guangzhou Baiyunshan Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in pharmaceutical innovations.
Collaborations
Shiqi has collaborated with several professionals in his field, including Ming Zhao and Xueyun Jiang, who is a prominent female scientist. These collaborations have further enhanced his research and development efforts.
Conclusion
Shiqi Peng's innovative work in the field of thrombolytic agents showcases his dedication to advancing medical science. His patents reflect a commitment to developing effective treatments for thrombus-related conditions.